Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 164 matching trials from the live ClinicalTrials.gov search.
Conditions
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
Interventions
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Conditions
Human Papillomavirus Vaccination
Interventions
Counseling
Behavioral
Lead sponsor
Plan A Health, Inc
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Louise, Mississippi
Completed Not applicable Interventional Accepts healthy volunteers

High and Low Resource Interventions to Promote HPV Vaccines

NCT03824093
Conditions
Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication, Satisfaction
Interventions
AFIX Only, AFIX+ Provider Communication Training
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Completed Not applicable Interventional Accepts healthy volunteers

mHealth Intervention in Increasing HPV Vaccinations in College Students

NCT02960100
Conditions
Healthy Subject
Interventions
Informational Intervention, Media Intervention, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 25 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Infections, Papillomavirus
Interventions
HPV 16/18 L1 AS04, HPV-16/18/31/45 L1 AS04 Formulation 1, HPV-16/18/31/45 L1 AS04 Formulation 2, HPV-16/18/31/45 L1 AS04 Formulation 3, HPV-16/18/31/45 L1 AS04 Formulation 4, HPV-16/18/31/45 L1 AS04 Formulation 5, HPV-16/18/31/45 L1 AS04 Formulation 6
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 25 Years · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
5
States / cities
Aurora, Colorado • Golden, Colorado • Kingston, Rhode Island + 1 more
Conditions
Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy, Cancer Vaccine
Interventions
Docetaxel, Cisplatin, PRGN-2009
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Papilloma Virus, Human
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
Not listed
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 15 more
Conditions
HPV-Associated Cancers
Interventions
Ad-E6E7, MG1-E6E7, Atezolizumab
Biological
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Miami, Florida • Billings, Montana • New York, New York + 2 more
Conditions
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions
pNGVL4aCRTE6E7L2
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Conditions
Human Papilloma Virus, Human Papilloma Virus Vaccine
Interventions
CDC 4 Pillars Program
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Albany, Georgia • Atlanta, Georgia • Lithonia, Georgia
Completed No phase listed Observational Accepts healthy volunteers

Alternate Dosing Schedules Study for HPV Vaccine (ADS)

NCT02280642
Conditions
Cervical Cancer, Genital Warts
Interventions
Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late, Both doses late
Biological
Lead sponsor
Duke University
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Parents in Appalachia Receive Education Needed for Teen Project

NCT01901770
Conditions
Healthy, Human Papilloma Virus Infection
Interventions
educational intervention
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Gardasil in Mid-Adult Males (MAM)

NCT01432574
Conditions
Human Papillomavirus
Interventions
Gardasil
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
27 Years to 45 Years · Male only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Human Papillomavirus (HPV) Vaccines
Interventions
Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
1,296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Active, not recruiting Not applicable Interventional

HPV Vaccine Reminders - SEARCH II Study

NCT06161831
Conditions
Human Papillomavirus Vaccination
Interventions
Text Message/automated phone reminder
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 14 Years · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Papillomavirus Infections
Interventions
9vHPV vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 26 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
14
States / cities
Daly City, California • Oakland, California • Roseville, California + 10 more
Completed No phase listed Observational Results available

SDH of HPV Vaccine Completion

NCT03709602
Conditions
Human Papilloma Virus
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
3,076 participants
Timeline
2019
U.S. locations
1
States / cities
Durham, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

HPV Message Testing and Social Media Campaign

NCT03747302
Conditions
Vaccine, Human Papilloma Virus
Interventions
Social Media Message about HPV and HPV vaccine, Social media message about risk of electronic cigarettes.
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
1,043 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Human Papilloma Virus vaccine (GARDASIL 9)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Let's K-Talk - HPV Study for Ethnic Koreans

NCT05884697
Conditions
Human Papillomavirus Viruses, Papillomavirus Vaccines
Interventions
K-Talk Intervention (Storytelling and K-Bot), Storytelling Intervention, K-Bot Intervention, Written Information
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

Preparedness Study - HPV Vaccine

NCT01489527
Conditions
Sexual Transmission of Infection
Interventions
Gardasil Vaccine, Placebo
Biological · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Anal Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Penile Cancer, Vulvar Cancer
Interventions
human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • Morristown, New Jersey + 1 more
Conditions
Infections, Papillomavirus
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California